Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

China Aoxing Given Preferred Status for Cancer Pain Drug

publication date: Nov 27, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Aoxing Pharmaceutical Company received “designated manufacturer status” for Tilidine, an opioid medication for cancer pain, from the China State Food & Drug Administration. The designation means China Aoxing will have five years of manufacturing exclusivity for Tilidine. Under present rules, China allows only 13 companies to produce narcotic drugs such as Tilidine, and even more important, only one to three companies are permitted to produce the active pharmaceutical ingredients of the medication. The low-risk business plan of China Aoxing is to introduce Western-style pain drugs to China. More details...

Stock Symbol: (OTCBB: CAXG)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Other Events

China Pharmaceutical R&D Summit
April 23-26, 2012
Shanghai, China


Biosimilars Asia 2012
April 23-26, 2012
Shanghai, China


Vaccines China 2012
April 23-26, 2012
Shanghai, China

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners